Event > Webinar >

Harnessing liver-on-a-chip models for drug safety

Improving data translatability between preclinical testing and clinical applications is crucial for advancing drug safety assessment. A major challenge lies in enhancing the predictivity of standard toxicology workflows to better identify complex or species-specific toxicity risks. In this webinar, Emily Richardson will describe how liver microphysiological systems (MPS), also called liver-on-a-chip technology, can improve safety testing by providing greater physiological relevance, longevity, and cross-species insights to support research decisions and therapeutic development.